Cargando…

Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer

Ovarian cancer has a high case fatality rate, but patients who have no visible residual disease after surgery have a relatively good prognosis. The presence of any cancer cells left in the peritoneal cavity after treatment may precipitate a cancer recurrence. In many cases, these cells are occult an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jie Wei, Wong, Fabian, Szymiczek, Agata, Ene, Gabrielle E. V., Zhang, Shiyu, May, Taymaa, Narod, Steven A., Kotsopoulos, Joanne, Akbari, Mohammad R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532395/ https://www.ncbi.nlm.nih.gov/pubmed/37762691 http://dx.doi.org/10.3390/ijms241814388

Ejemplares similares

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
por: Stecklein, Shane R., et al.
Publicado: (2023)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
por: Lazurko, Caitlin, et al.
Publicado: (2023)

Prediction of the treatment response in ovarian cancer: a ctDNA approach
por: Sharbatoghli, Mina, et al.
Publicado: (2020)

Salpingectomy and the Risk of Ovarian Cancer in Ontario
por: Giannakeas, Vasily, et al.
Publicado: (2023)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer
por: Oikkonen, Jaana, et al.
Publicado: (2019)

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence
por: Marchi, Giovanni, et al.
Publicado: (2023)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer——A retrospective study of ctDNA
por: Zhang, Xuefei, et al.
Publicado: (2023)

Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients
por: Sharbatoghli, Mina, et al.
Publicado: (2022)

The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer
por: Yang, Yang, et al.
Publicado: (2022)

The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis
por: Faulkner, Lucy G., et al.
Publicado: (2022)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece
por: Koumpis, Chrissovaladis, et al.
Publicado: (2011)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer
por: Escudero, Laura, et al.
Publicado: (2021)

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
por: Gale, D., et al.
Publicado: (2022)

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review
por: Verzè, Michela, et al.
Publicado: (2022)

The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada
por: Narod, Steven A., et al.
Publicado: (2021)

Rapid development and use of patient-specific ctDNA biomarkers to avoid a “rash decision” in an ovarian cancer patient
por: Pandya, Deep, et al.
Publicado: (2019)

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
por: Abbosh, Christopher, et al.
Publicado: (2017)

Beyond the pill: contraception and the prevention of hereditary ovarian cancer
por: Xia, Yue Yin, et al.
Publicado: (2022)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA
por: He, Na, et al.
Publicado: (2018)

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
por: Abbosh, Christopher, et al.
Publicado: (2023)

Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application
por: Sivapalan, L., et al.
Publicado: (2021)

Identification of germline cancer predisposition variants during clinical ctDNA testing
por: Stout, Leigh Anne, et al.
Publicado: (2021)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
por: Zhao, Jianhua, et al.
Publicado: (2023)

Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
por: Domrazek, Kinga, et al.
Publicado: (2023)

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer
por: Kim, Shana J, et al.
Publicado: (2017)

Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients
por: Barbosa, Ana, et al.
Publicado: (2021)

A systematic review and meta-analysis of indirect comparison between miRNA and ctDNA in diagnosis of epithelial ovarian cancer
por: Fu, Xiaohang, et al.
Publicado: (2021)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_an3sfgi5b8gaf5hi2vbj2g7nd5